Multivariate Survival Analysis of a Comprehensive Clinical Trial of Rapamycin in Amyotrophic Lateral Sclerosis Explores Prognostic Factors and Survival Patterns in C9orf72 Carriers
Alex De Nardi, Alessio Paris, Mario Lauria, Ilaria Martinelli, Elisabetta Zucchi, Cecilia Simonini, Jessica Mandrioli, Luca Marchetti · 2026
Read Multivariate Survival Analysis of a Comprehensive Clinical Trial of Rapamycin in Amyotrophic Lateral Sclerosis Explores Prognostic Factors and Survival Patterns in C9orf72 Carriers by Alex De Nardi, Alessio Paris, Mario Lauria, Ilaria Martinelli, Elisabetta Zucchi, Cecilia Simonini, Jessica Mandrioli, Luca Marchetti (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13589253.txt.
Description
Amyotrophic lateral sclerosis, or ALS, weakens muscles over time, and patients live for very different lengths of time. Alex De Nardi and co-authors re-analyzed data in 2026 from a trial of the drug rapamycin in 63 ALS patients. They searched for factors that predict survival, using models that can weigh many measures at once and let them change over time.
Known risk factors held up, and the best models mixed nerve damage markers, blood measures, clinical scores, and immune signals. One small subgroup stood out: treated patients carrying a C9orf72 gene change lived longer than expected. With only six such patients, the authors call that result exploratory and ask for a larger, gene-stratified trial.
Catalog record
| CREATOR | Alex De Nardi, Alessio Paris, Mario Lauria, Ilaria Martinelli, Elisabetta Zucchi, Cecilia Simonini, Jessica Mandrioli, Luca Marchetti |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |